Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02915198 · ClinicalTrials.gov registry record · Phase 4
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
A Phase 4 study of Atherosclerosis and Prediabetic State, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 7,410
- Enrollment target
- 20
- Study locations
NCT02915198 is a Phase 4 study of Atherosclerosis and Prediabetic State that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 7,410 participants, above the 958-participant average among 69 other Atherosclerosis trials with a reported enrollment target (673% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT02915198, a Phase 4 study of Atherosclerosis and Prediabetic State, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 7,410 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin XR
Study Locations (20)
California
- VA Loma Linda Healthcare System, Loma Linda, CA - Loma Linda
- VA Long Beach Healthcare System, Long Beach, CA - Long Beach
- VA Palo Alto Health Care System, Palo Alto, CA - Palo Alto
- VA San Diego Healthcare System, San Diego, CA - San Diego
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA - West Los Angeles
Florida
- Bay Pines VA Healthcare System, Pay Pines, FL - Bay Pines
- North Florida/South Georgia Veterans Health System, Gainesville, FL - Gainesville
- Miami VA Healthcare System, Miami, FL - Miami
Arizona
- Phoenix VA Health Care System, Phoenix, AZ - Phoenix
- Southern Arizona VA Health Care System, Tucson, AZ - Tucson
Illinois
- Jesse Brown VA Medical Center, Chicago, IL - Chicago
- Edward Hines Jr. VA Hospital, Hines, IL - Hines
Arkansas
- Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR - Little Rock
Colorado
- Rocky Mountain Regional VA Medical Center, Aurora, CO - Aurora
Connecticut
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT - West Haven
Georgia
- Atlanta VA Medical and Rehab Center, Decatur, GA - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,410 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2029-09-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02915198
The ClinicalTrials.gov registry entry for NCT02915198 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 7,410 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 958-participant average among 69 other Atherosclerosis trials with a reported enrollment target (673% higher). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02915198 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02915198 about?
NCT02915198 is a clinical study titled "Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes". This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.
What is the current status of trial NCT02915198?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 7,410 participants. The study started on 2023-04-03. Estimated completion is 2029-09-28.
What conditions does trial NCT02915198 study?
This clinical trial studies the following conditions: Atherosclerosis, Prediabetic State, Metformin.
What interventions are being tested in trial NCT02915198?
The interventions under investigation include: Placebo (DRUG), Metformin XR (DRUG).
Who is sponsoring clinical trial NCT02915198?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02915198 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
COMPLETED · Phase 4
-
Improving Cardiovascular Risk Prediction Using Hand Held Carotid Ultrasonography Study
COMPLETED · Phase 4
-
Testosterone Replacement in Older Men and Atherosclerosis Progression
COMPLETED · Phase 4
-
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
COMPLETED · Phase 4
-
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.